Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1600 of 3499 entries
View as:

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00288093 Org: User:
Start: 12/20/06 End: 12/28/12 Due: 12/28/13

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02194829 Org: User:
Start: 08/19/14 End: 12/21/22 Due: 12/21/23

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00085371 Org: User:
Start: 07/31/04 End: - Due: -

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01835145 Org: User:
Start: 07/31/13 End: 11/01/19 Due: 11/01/20

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01159301 Org: User:
Start: 06/30/10 End: - Due: -

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019695 Org: User:
Start: 03/31/99 End: 03/31/05 Due: 03/31/06

Genetics of Familial Testicular Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00342537 Org: User:
Start: 01/02/04 End: 07/14/20 Due: 07/14/21

AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01253447 Org: User:
Start: 10/31/10 End: 04/30/14 Due: 04/30/15

A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor

Phase: N/A Priority: Normal
NCT ID: NCT00001509 Org: User:
Start: 07/31/96 End: 05/31/00 Due: 05/31/01

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01776008 Org: User:
Start: 01/31/13 End: 05/05/15 Due: 05/05/16

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02601209 Org: User:
Start: 11/30/15 End: 07/11/22 Due: 07/11/23

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02111863 Org: User:
Start: 02/21/14 End: 07/21/16 Due: 07/21/17

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00693433 Org: User:
Start: 12/31/08 End: - Due: -

Lovastatin in Treating Patients At High Risk of Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00462280 Org: User:
Start: 05/31/07 End: 02/29/12 Due: 02/28/13

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00042809 Org: User:
Start: 05/31/02 End: - Due: -

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00075881 Org: User:
Start: 01/31/04 End: 10/31/12 Due: 10/31/13

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06029270 Org: User:
Start: 07/15/24 End: 04/30/29 Due: 04/30/30

The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00001189 Org: User:
Start: 12/31/83 End: 04/30/01 Due: 04/30/02

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase: N/A Priority: Normal
NCT ID: NCT00520975 Org: User:
Start: 11/30/07 End: 10/31/15 Due: 10/31/16

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT02337517 Org: User:
Start: 09/08/15 End: 06/28/18 Due: 06/28/19

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04092283 Org: User:
Start: 04/29/20 End: 12/31/28 Due: 12/31/29

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02834013 Org: User:
Start: 01/30/17 End: 05/01/26 Due: 05/01/27

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Phase: N/A Priority: Normal
NCT ID: NCT06203600 Org: User:
Start: 06/24/24 End: 10/31/27 Due: 10/31/28

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03793179 Org: User:
Start: 04/05/19 End: 09/30/27 Due: 09/30/28

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03737981 Org: User:
Start: 01/31/19 End: 06/09/26 Due: 06/09/27